Zacks
  • Home
  • Analyst Bios
  • Research Reports
    • Companies by Analyst
      • Biotech - David Bautz, PhD
      • Bank & Finance – Ann Heffron, CFA, CPA
      • Biotech - John Vandermosten, CFA
      • Special Situations – Steven Ralston, CFA
      • Med-Tech – Brian Marckx, CFA
      • Technology – Lisa Thompson
      • Senior Analyst – M. Marin
      • Healthcare - Beth Senko, CFA
    • Companies by Name
  • Distribution
    • Institutional Distribution
    • Retail Distribution
    • Social Media
    • RSS Feeds
  • Our Partners
    • IR Firms
  • Contact
  • Subscribe
    • Free Weekly Digest
    • Zacks SCR Premium
Brian Marckx, CFA, Senior Med-Tech Analyst

Brian Marckx, CFA, is the Senior Med-Tech Analyst with Zacks Small-Cap Research. He has nearly 25 years’ experience as an analyst in both buy and sell-side roles and in fixed-income, structured finance and equity asset classes. Subsequent to joining Zacks in 2007 as a large cap pharma and biotechnology analyst, Brian has gained more than a decade’s worth of experience covering over 100 small and micro-cap companies in the medical technology space. The focus of his coverage has included every sub-industry within med-tech and spanned a wide range of biologics, chemicals, devices, diagnostics, equipment, labs, products, services, software, supplies and more.



Prior to joining Zacks, Brian worked as a high-yield bond analyst on Wachovia Securities' institutional trading desks where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Brian has been quoted in numerous publications including The Wall Street Journal, Barron's, Bloomberg-Businessweek and Kilpinger and his work has been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche and Pharmaceutical Manufacturing. Brian graduated with a B.S. in Finance from St. John Fisher College and received his MBA from Wake Forest University. He is a holder of the Chartered Financial Analyst (CFA) designation.


Follow @bmarckxCFA

Brian Marckx's Universe Includes




























Latest

Notes in the Press

March 4, 2021 BCLI: Awaiting BrainStorm’s Decision on NurOwn® BLA Filing…
March 3, 2021 Deep Yellow Limited Releases Positive PFS with Maiden Reserve on Tumas Project; Board Approves Proceeding Directly to a DFS
March 2, 2021 TRC: Recent Updates Imply Strong Positives For Development Plans
March 1, 2021 IDBA: Idex Biometrics Reports 2020 Earnings and Lists on NASDAQ
March 1, 2021 ELYS: Expanding Strategic Relationship to Leverage Growth Opportunities
March 1, 2021 ACHV: Data Presentation on Smoker and E-Cigarette User Attitudes and Quitting Perceptions
March 1, 2021 DSS Establishes a JV to Pursue a Digital Securities Exchange in the US and Adds Marketing Partners
March 1, 2021 KTRA: 2Q:21 Update & Target Price Increase
March 1, 2021 CVM: 1Q:21 Financial Update
March 1, 2021 BIOX: Bioceres Crop Solutions is poised to benefit from regulatory approvals in China for HB4 soybeans and in Brazil for HB4 wheat
 

Invalid login, please try again. You have retries remaining before your account will be locked.

Your account is locked and it will be unlocked automatically in minutes.

User ID:
Password:
Remember my ID:

COPYRIGHT © ZACKS INVESTMENT RESEARCH 2020
  • Disclaimer
  • Privacy Policy
  • Site Map
Tweet Follow @ZacksSmallCap
Powered By Q4 Inc. 5.52.0.6